BMEAHealthcare · BiotechnologyThe 7 Wall Street analysts covering Biomea Fusion, Inc. hold a median 12-month price target of $7 — +410.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 55 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Biomea Fusion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (84): Sales and profits are climbing, and climbing faster than before.
Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BMEA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +410.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 May 2026 | Citizens | Initiates | Market Outperform | $9.00 |
| 28 Apr 2026 | D. Boral Capital | Maintains | Buy | $12 |
| 8 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2026 | Citigroup | Maintains | Buy | — |
| 25 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 13 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 10 Nov 2025 | Citigroup | Maintains | Buy | — |
| 5 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 Aug 2025 | Jefferies | Initiates | Buy | — |
| 11 Aug 2025 | Citigroup | Maintains | Buy | — |
| 6 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Aug 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 21 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 July 2025 | Citigroup | Maintains | Buy | — |
| 24 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 June 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMEA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Biomea Fusion, Inc. returned −18.5% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 12% of US stocks
Cheaper than 69% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 6% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biomea Fusion, Inc. has a market value of $99.3M and an enterprise value of $61.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$32.5M.
Free cash flow in the twelve months to 30 June 2026: −$47.2M.
Trailing P/E: −1.2×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Biomea Fusion, Inc. employs 37 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Biomea Fusion, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Biomea Fusion, Inc. shares traded down nearly 19% on Wednesday as investors reacted to the company's decision to terminate its proposed public equity offering. The announcement led to a sharp decline in the stock's value.
Why it matters — The termination of the equity offering is a notable capital-raising development that could affect Biomea Fusion's funding situation and market sentiment.
Biomea Fusion announced the termination of its proposed public offering of securities, previously announced on September 22, 2026. The company's management determined that current market conditions were not conducive to an offering on terms favorable to stockholders, and no securities were sold in connection with the offering.
Why it matters — BMEA watchers would care because it means the clinical-stage company has not raised new capital through this offering and will need to rely on existing resources, with no share dilution occurring.
Biomea Fusion announced it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase common stock. The company also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares and warrants offered, with all securities to be sold by Biomea.
Why it matters — A BMEA watcher would care because the proposed offering could affect the company's share count and capital position as a clinical-stage diabetes and obesity company.
Zacks Investment Research reported that Biomea Fusion, Inc. (BMEA) reached a key level of support, and its 50-day simple moving average crossed above its 200-day simple moving average—a technical pattern known as a "golden cross." The item frames this as indicating a bright technical outlook for the stock.
Why it matters — BMEA watchers would care because the golden cross and support level are technical signals that reflect a shift in the stock's market momentum and trend direction.
Biomea Fusion announced that members of its management team will participate in Citi's 2026 Biopharma Back to School Conference, holding one-on-one investor meetings on September 10, 2026, in New York, New York.
Why it matters — This is an opportunity for the company's management to engage directly with investors at a major biopharma conference, which could raise the company's visibility.
The 7 Wall Street analysts covering Biomea Fusion, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Biomea Fusion, Inc., 6 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biomea Fusion, Inc. 55 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Biomea Fusion, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +410.9% from the last close, and Ticker Nerd's factor model ranks Biomea Fusion, Inc. 55 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Biomea Fusion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMEA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.
Biomea Fusion, Inc. returned -18.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases.
The most recent item we track (Benzinga, 23 Sept 2026): "Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data". Biomea Fusion, Inc. shares traded down nearly 19% on Wednesday as investors reacted to the company's decision to terminate its proposed public equity offering. The announcement led to a sharp decline in the stock's value.
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases. Its current pipeline centers on icovamenib, a menin inhibitor being studied across multiple diabetes programs, and BMF-650, an oral GLP-1 receptor agonist in development for obesity. The company’s work is built around covalent chemistry and precision drug design, with an emphasis on therapies intended to address biologically defined patient groups. Biomea Fusion Inc. also explores applications in genetically defined cancers through its broader small-molecule research platform. Headquartered in San Carlos, California, Biomea Fusion Inc. plays a role in the biopharmaceutical market as a developer of investigational treatments aimed at challenging endocrine and metabolic conditions.
CEO Dr. Michael J. M. Hitchcock Ph.D. · 37 employees · United States · https://biomeafusion.com
